Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 609-615 , September 2010

Role of MRI in diagnosis and treatment of multiple sclerosis

  • Mohammad Ali Sahraian

      Affiliations

    • Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Iran
    • Corresponding Author InformationCorresponding author at: Department of Neurology, Sina Hospital, Hassan Abad Square, Tehran, Iran. Tel.: +98 21 66706142/3.
    • ,
  • Arman Eshaghi

      Affiliations

    • Sina MS Research Center, Sina Hospital, Tehran University of Medical Sciences, Iran

Received 9 February 2010 ,Revised 3 March 2010 ,Accepted 23 March 2010.

References 

  1. Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet. 1981;2:1063–1066
  2. Sormani MP, Molyneux PD, Gasperini C, Barkhof F, Yousry TA, Miller DH, et al. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. J Neurol Neurosurg Psychiatry. 1999;66:465–469
  3. Filippi M, Rocca MA. Conventional MRI in multiple sclerosis. J Neuroimag. 2007;17:3S–9S
  4. O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998;121:495–503
  5. Ormerod IE, Miller DH, McDonald WI, du Boulay EP, Rudge P, Kendall BE, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain. 1987;110:1579–1616
  6. Bø L, Vedeler CA, Nyland H, Trapp BD, Mørk SJ, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocytic infiltration. Mult Scler. 2003;9:231–323
  7. Zhao GJ, Koopmans RA, Li DK, Bedell L, Paty DW. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group. Neurology. 2000;11:200–206
  8. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42:783–793
  9. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance imaging in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol. 1989;27:43–49
  10. Koopmans RA, Li DK, Oger JJ, Mayo J, Paty DW. The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology. 1989;39:959–963
  11. Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx. 2005;2:277–303
  12. Bitsch A, Bruck W. MRI-pathological correlates in MS. Int MSJ. 2002;8:89–95
  13. Neema M, Stankiewicz J, Arora A, Dandamudi VS, Batt CE, Guss ZD, et al. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimag. 2007;17:16s–21s
  14. Adams JG, Melhem ER. Clinical usefulness of T2-weighted fluid attenuated inversion recovery MR imaging of the CNS. AJR Am J Roentgenol. 1999;172:529–536
  15. Hajnal JV, De Coene B, Lewis PD, Baudouin CJ, Cowan FM, Pennock JM, et al. High signal regions in normal white matter shown by heavily T2-weighted CSF nulled IR sequences. J Comput Assist Tomogr. 1992;16:506–513
  16. Miller DH, Rudge P, Johnson G, Kendall BE, Macmanus DG, Moseley IF, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1998;111:927–939
  17. He J, Grossman RI, Ge Y, Mannon LG. Enhancing patterns in multiple sclerosis: evolution and persistence. AJNR Am J Neuroradiol. 2001;22:664–669
  18. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology. 2001;57:731–733
  19. Bagnato F, Jeffries N, Richert ND, Stone RD, Ohayon JM, McFarland HF, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126:1782–1789
  20. van Waesberghe JH, van Walderveen MA, Castelijns JA, Scheltens P, Lycklama à Nijeholt GJ, Polman CH, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998;19:675–683
  21. Ciccarelli O, Giugni E, Paolillo A, Mainero C, Gasperini C, Bastianello S, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 1999;6:455–459
  22. Masdeu JC, Moreira J, Trasi S, Visintainer P, Cavaliere R, Grundman M. The open ring. A new imaging sign in demyelinating disease. J Neuroimag. 1996;6:104–107
  23. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999;353:964–969
  24. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in MS. Neurology. 1996;46:379–384
  25. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effect of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997;120:1149–1161
  26. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008;7:615–625
  27. Dousset V, Brochet B, Deloire MS, Lagarde L, Barroso B, Caille JM, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol. 2006;27:1000–1005
  28. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27:455–461
  29. Neema M, Stankiewicz J, Arora A, Guss ZD, Bakshi R. MRI in Multiple Sclerosis: What's Inside the Toolbox?. Neurotherapeutics. 2007;4:601–617
  30. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Brück W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol. 2001;49:793–796
  31. Bagnato F, Evangelou IE, Gallo A, Gaindh D, Yao K. The effect of INF b on black holes in patients with multiple sclerosis. Expert Opin Biol Ther. 2007;7:1079–1091
  32. Sahraian MA, Radue EW, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution and clinical correlation. Acta Neurol Scand. 2009;
  33. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158–170
  34. Ge Y, Grossman RI, Udupa JK, Babb JS, Nyúl LG, Kolson DL. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology. 2000;214:665–670
  35. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:327–337
  36. Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004;127:1101–1107
  37. Lin X, Blumhardt LD. Inflammation and atrophy in multiple sclerosis: MRI associations with disease course. J Neurol Sci. 2001;189:99–104
  38. Luks TL, Goodkin DE, Nelson SJ, Majumdar S, Bacchetti P, Portnoy D, et al. A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis. Mult Scler. 2000;5:332–337
  39. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003;7:1157–1162
  40. Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M, et al. Brain atrophy in relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology. 2000;3:665–670
  41. Anderson VM, Fox NC, Miller DH. Magnetic resonance imaging msures of brain atrophy in multiple sclerosis. J Magn Reson Imaging. 2006;23:605–618
  42. Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol. 2002;59:1572–1576
  43. Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimag. 2004;14(3 Suppl.):54S–64S
  44. Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology. 2002;59:688–694
  45. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–127
  46. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846
  47. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6:677–686
  48. Lovblad KO, Anzalone N, Dorfler A, Essig M, Hurwitz B, Kappos L. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol. 2009;(December):[Epub ahead of print]
  49. Rovira A, Swanton J, Tintoré M, Huerga E, Barkhof F, Filippi M, et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol. 2009;66:587–592
  50. Rolak LA, Fleming JO. The differential diagnosis of multiple sclerosis. Neurologist. 2007;13:57–72
  51. Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol. 2006;5:841–852
  52. Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment. Ann Neurol. 2006;59:597–605
  53. Rovaris M, Filippi M, Falautano M, Minicucci L, Rocca MA, Martinelli V, et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology. 1998;50:1601–1608
  54. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 1996;47:1469–1476
  55. Brex PA, Ciccarelli O, O’Riordal JL, Sailer M, Thompson AJ, Miller DH, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;356:158–164
  56. Rovaris M, Filippi M. Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. Neurol Sci. 2005;26:S204–S208
  57. Paty DW, Li DK. Interferon _1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:662–667
  58. Fazekas F, Sorenson PS, Comi G, Filippi M. MRI to monitor treatment efficacy in multiple sclerosis. J Neuroimag. 2007;17:50S–55S
  59. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009;65:268–275
  60. Filippia M, Roccaa MA, Arnold DL, Bakshi R, Barkhof F, De Stefano N, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol. 2006;13:313–325
  61. Bot J, Barkhof F, Polman CH, Lycklama à Nijeholt GJ, de Groot V, Bergers E, et al. Spinal cord abnormalities in recently diagnosed MS patients. Added value of spinal MRI examination. Neurology. 2004;62:226–233
  62. Nijeholt GJ, van Walderveen MA, Castelijns JA, van Waesberghe JH, Polman C, Scheltens P, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain. 1998;121:687–697
  63. O’Riordan JI, Losseff NA, Phatouros C, Thompson AJ, Moseley IF, MacManus DG, et al. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry. 1998;64:353–357
  64. Thorpe JW, Kidd D, Moseley IF, Kenndall BE, Thompson AJ, MacManus DG, et al. Serial gadolinium enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology. 1996;46:373–378
  65. Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:15–19
  66. Gass A, Filippi M, Rodegher ME, Schwartz A, comi G, Hennerici MG. Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI. Neurology. 1998;50:548–550
  67. Stevenson VL, Leary SM, Losseff NA, Parker GJ, Barker GJ, Husmani Y, et al. Spinal cord atrophy and disability inMS: a longitudinal study. Neurology. 1998;51:234–238
  68. Brinar VV, Habek M, Zadro I, Barun B, Ozretic D, Vranjes D. Current concepts in the diagnosis of transverse myelopathies. Clin Neurol Neurosurg. 2008;110:919–927
  69. Brinar VV, Habek M, Brinar M, Malojcic B, boban M. The differential diagnosis of acute transverse myelitis. Clin Neurol Neurosurg. 2006;108:278–283
  70. Sahraian MA, Moinfar Z, Khorramnia S, Mohammad ebrahim M. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol. 2010;(January):[Epub ahead of print]
  71. Agosta F, Filippi M. MRI of spinal cord in multiple sclerosis. J Neuroimag. 2007;17:46S–49S
  72. Ge Y. Multiple sclerosis: the role of MR imaging. Am J Neuroradiol AJNR. 2006;27:1165–1176

PII: S0303-8467(10)00093-4

doi: 10.1016/j.clineuro.2010.03.022

Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 609-615 , September 2010

Article Tools

* Image Usage & Resolution